Nova-X
On sale on the US market (according to the DSLD)
Gaspari Nutrition, food supplement from the US market
Nova-X (Gaspari Nutrition), a food supplement au code-barres 646511022829, is described by its US market label. If sold in France, it would be subject to 2 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Conditions légales
Prunus africana (Hook. f.) Kalkman: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Gaspari Nutrition
- Barcode
- 646511022829
- Form
- Tablet
- One serving
- 1 tablet
- Servings
- up to 2 servings per day
- Other ingredients (in English, as written)
- LipoAbsorb Matrix:, Alcohol, Glyceryl Stearate, Oleic Acid, Linoleic Acid, Linolenic Acid, Ascorbyl Palmitate, Microcrystalline Cellulose, Carboxymethylstarch Sodium Salt, Silica, Colloidal Anhydrous, Magnesium Stearate, Enteric Coating, FD&C Blue #1, FD&C Red #40
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Androsterone | Hormone | 50 mg |
| Mucuna pruriens extract (Mucuna pruriens) | Plant | 250 mg |
| Toxicodendron vernicifluum extract | Plant | 100 mg |
| Diosterol brand Dioscorea nipponica makino 50-67:1 extract | Plant | 200 mg |
| Progenin III | Other substance | not stated |
| Protodioscin | Other substance | not stated |
| Iridoid Glycosides | Other substance | not stated |
| Diosgenin | Other substance | not stated |
| 5a-Hydroxy Laxogenin | Other substance | not stated |
| DHT Inhibiting Complex | Blend | 210 mg |
| Pygeum africanum bark extract (Prunus africana) | Plant | not stated |
| 13% total Sterols | Fat | 6.5 mg |
| Saw Palmetto Liposterolic berry extract (Serenoa repens) | Plant | not stated |
| N-Methyl-D-Aspartic Acid | Other substance | 30 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Nova-X
Entered into DSLD on 22 May 2015. Withdrawn from the US market on 22 September 2017 (according to the DSLD).- Active ingredient removed : N-Methyl-D-Aspartic Acid (30 mg)
- Same quantity, different name: guaranteed 13% total Sterols in this version; 13% total Sterols on the displayed label (6.5 mg)
- Same quantity, different name: Saw palmetto in this version; Saw Palmetto Liposterolic berry extract on the displayed label (quantity not stated)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Pygeum africanum bark extract
Read the warning, when it applies and the studies cited
PYGEUM - PRUNUS AFRICANA
Route of administration: Oral
Cautions and warnings
Condition of application: Standardized extracts making a claim for symptoms of benign prostatic hyperplasia (adult males).
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (Goldman and Ausiello 2004).
Sources cited by Health Canada (1)
- Goldman L, Ausiello D. Cecil Textbook of Medicine. 22nd edition. Philadelphia (PA): Saunders; 2004.
Condition of application: Non-standardized preparations for adults (i.e., including women) (safety only).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
- Saw Palmetto Liposterolic berry extract
Read the warning, when it applies and the studies cited
SAW PALMETTO – SERENOA REPENS
Route of administration: Oral
Cautions and warnings
Condition of application: All subpopulations.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Adult males only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.
Condition of application: Adult females only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
Contraindications
Condition of application: Adult females only.
Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Gaspari Nutrition
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Nova-X (Gaspari Nutrition): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/646511022829-nova-x-gaspari-nutrition, updated 22 December 2017.